- Marketwired•5 hours ago
Bio-Rad Laboratories, Inc. , a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2016 on Thursday, February 23, ...
- PR Newswire•6 hours agoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Rad Laboratories, Inc. - BIO
NEW YORK, Jan. 18, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company") (NYSE: BIO). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980. On May 27, 2015, Bio-Rad's former General Counsel Sanford Wadler filed a lawsuit alleging that he was fired in 2013 after raising concerns to the Company's audit committee about bribery practices in China and for refusing to turn a blind eye to corruption. On this news, the Company's stock fell $1.63, or $1.13%, to close at $142.36 on May 28, 2015.
- The Wall Street Journal•yesterday
Bio-Rad Laboratories Inc. has agreed to acquire RainDance Technologies Inc., a venture-backed developer of genomics tools that once aspired to a public listing.
BIO-B : Summary for Bio-Rad Laboratories, Inc. Clas - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO-B)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||182.65 - 187.45|
|52 Week Range||124.50 - 188.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||56.39|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|